CL2017002817A1 - Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue - Google Patents

Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue

Info

Publication number
CL2017002817A1
CL2017002817A1 CL2017002817A CL2017002817A CL2017002817A1 CL 2017002817 A1 CL2017002817 A1 CL 2017002817A1 CL 2017002817 A CL2017002817 A CL 2017002817A CL 2017002817 A CL2017002817 A CL 2017002817A CL 2017002817 A1 CL2017002817 A1 CL 2017002817A1
Authority
CL
Chile
Prior art keywords
compounds
mono
inhibitors
viral replication
indole derivatives
Prior art date
Application number
CL2017002817A
Other languages
English (en)
Spanish (es)
Inventor
Pierre Jean-Marie Bernard Raboisson
Bart Rudolf Romanie Kesteleyn
Jean-François Bonfanti
Tim Hugo María Jonckers
Dorothée Alice Marie-Eve Bardiot
Arnaud Didier M Marchand
Original Assignee
Univ Leuven Kath
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath, Janssen Pharmaceuticals Inc filed Critical Univ Leuven Kath
Publication of CL2017002817A1 publication Critical patent/CL2017002817A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08Bridged systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2017002817A 2015-05-08 2017-11-07 Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue CL2017002817A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166900 2015-05-08
EP16163342 2016-03-31

Publications (1)

Publication Number Publication Date
CL2017002817A1 true CL2017002817A1 (es) 2018-05-11

Family

ID=56026812

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002817A CL2017002817A1 (es) 2015-05-08 2017-11-07 Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue

Country Status (39)

Country Link
US (5) US10696632B2 (OSRAM)
EP (2) EP3896072B1 (OSRAM)
JP (4) JP6752821B2 (OSRAM)
KR (2) KR102610491B1 (OSRAM)
CN (3) CN107873022B (OSRAM)
AU (2) AU2016259677B2 (OSRAM)
BR (1) BR112017023904A2 (OSRAM)
CA (1) CA2981845C (OSRAM)
CL (1) CL2017002817A1 (OSRAM)
CO (1) CO2017012381A2 (OSRAM)
CR (2) CR20200152A (OSRAM)
CY (1) CY1124548T1 (OSRAM)
DK (1) DK3294738T3 (OSRAM)
EA (1) EA034978B1 (OSRAM)
EC (2) ECSP17073878A (OSRAM)
ES (2) ES2941674T3 (OSRAM)
GT (1) GT201700234A (OSRAM)
HR (1) HRP20210675T1 (OSRAM)
HU (1) HUE054724T2 (OSRAM)
IL (2) IL255430B (OSRAM)
JO (2) JOP20160086B1 (OSRAM)
LT (1) LT3294738T (OSRAM)
MD (1) MD3294738T2 (OSRAM)
MX (2) MX391754B (OSRAM)
MY (1) MY198339A (OSRAM)
NI (1) NI201700137A (OSRAM)
PE (2) PE20180232A1 (OSRAM)
PH (1) PH12017502000B1 (OSRAM)
PL (1) PL3294738T3 (OSRAM)
RS (1) RS62029B1 (OSRAM)
SG (1) SG10201900315SA (OSRAM)
SI (1) SI3294738T1 (OSRAM)
SM (1) SMT202100367T1 (OSRAM)
SV (1) SV2017005557A (OSRAM)
TW (2) TWI744963B (OSRAM)
UA (2) UA128183C2 (OSRAM)
UY (2) UY36674A (OSRAM)
WO (1) WO2016180696A1 (OSRAM)
ZA (2) ZA201707524B (OSRAM)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
BR112017006708A2 (pt) * 2014-10-01 2017-12-26 Janssen Pharmaceuticals Inc indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
HRP20190199T1 (hr) * 2014-10-01 2019-04-05 Janssen Pharmaceuticals, Inc. Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
HUE054936T2 (hu) 2016-03-31 2021-10-28 Janssen Pharmaceuticals Inc Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai
EA201892216A1 (ru) 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
US10730884B2 (en) 2016-04-01 2020-08-04 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US11407715B2 (en) 2017-05-22 2022-08-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
UA125970C2 (uk) 2017-05-22 2022-07-20 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
IL292970A (en) * 2019-11-15 2022-07-01 Janssen Pharmaceuticals Inc Treatment and prevention of dengue disease
WO2022094817A1 (en) 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
WO2022094816A1 (en) 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
CN113024440B (zh) * 2021-03-17 2023-05-16 凯莱英医药集团(天津)股份有限公司 连续化合成取代吲哚-2-羧酸的方法
KR20240027735A (ko) 2021-06-29 2024-03-04 얀센 파마슈티칼즈, 인코포레이티드 (s)-2-(4-클로로-2-메톡시페닐)-2-((3-메톡시-5-(메틸설포닐)페닐)아미노)-1-(1h-인돌-3-일)에테논유도체의 제조 방법
JP2025517683A (ja) 2022-05-12 2025-06-10 ヤンセン ファーマシューティカルズ,インコーポレーテッド デングウイルス感染症の治療及び/又は予防
CN115521307B (zh) * 2022-09-30 2023-09-22 甘肃皓天医药科技有限责任公司 一种5-卤代-7-氮杂吲哚的制备方法
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease
CN119306651B (zh) * 2024-10-11 2025-12-05 山东大学 一种吲哚3-酰胺类衍生物及其制备方法与应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1200899A (en) 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
AU2002364566B2 (en) 2001-12-12 2009-03-26 Conforma Therapeutics Corporation Assays and implements for determining and modulating HSP90 binding activity
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
MX2007008587A (es) 2005-01-14 2007-09-07 Genelabs Tech Inc Derivados de indol para tratamiento de infecciones virales.
EA200701669A1 (ru) 2005-02-09 2008-02-28 Мидженикс Инк. Композиции и способы лечения или предотвращения инфекций, вызванных вирусами семейства flaviviridae
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
MX338530B (es) 2008-06-03 2016-04-21 Siga Technologies Inc Inhibidores de molecula pequeña para el tratamiento o prevencion de infeccion de virus del dengue.
EP2326631A4 (en) * 2008-08-18 2012-03-21 Univ Yale MIF MODULATORS
ES2612731T3 (es) * 2008-08-19 2017-05-18 Janssen Pharmaceutica Nv Antagonistas de receptores al frío de mentol
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
NZ600816A (en) 2010-01-15 2014-08-29 Gilead Sciences Inc Inhibitors of flaviviridae viruses
EP2552211A4 (en) 2010-03-26 2013-10-23 Glaxo Group Ltd INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
SG11201602748XA (en) 2013-10-23 2016-05-30 Janssen Sciences Ireland Uc Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
ES2687498T3 (es) 2014-01-31 2018-10-25 Bristol-Myers Squibb Company Macrociclos con grupos P2¿ heterocíclicos como inhibidores del factor XIa
AU2015271689C1 (en) 2014-06-04 2019-01-17 Fred Hutchinson Cancer Research Center Expansion and engraftment of stem cells using Notch 1 and/or Notch 2 agonists
PT3926051T (pt) 2014-06-04 2024-06-20 Amgen Inc Métodos de colheita de culturas de células de mamíferos
BR112017006708A2 (pt) 2014-10-01 2017-12-26 Janssen Pharmaceuticals Inc indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
NO2721243T3 (OSRAM) 2014-10-01 2018-10-20
HRP20190199T1 (hr) 2014-10-01 2019-04-05 Janssen Pharmaceuticals, Inc. Mono- ili di-supstituirani derivati indola kao inhibitori replikacije denga virusa
WO2016057905A1 (en) 2014-10-10 2016-04-14 Rutgers, The State University Of New Jersey Polymerase chain reaction primers and probes for mycobacterium tuberculosis
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US11096910B2 (en) 2015-07-22 2021-08-24 Max Delbruck-Centrum Fur Molekulare Medizin Metabolically robust analogs of CYP-eicosanoids for the treatment of cardiac disease
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3002214C (en) 2015-11-03 2022-01-04 Zoetis Services Llc Sol-gel polymer composites and uses thereof
EA201892216A1 (ru) 2016-03-31 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
HUE054936T2 (hu) 2016-03-31 2021-10-28 Janssen Pharmaceuticals Inc Helyettesített indol-származékok mint a dengue-vírus replikációjának inhibitorai
JP6788683B2 (ja) 2016-03-31 2020-11-25 武田薬品工業株式会社 複素環化合物
SG11201808622SA (en) 2016-04-01 2018-10-30 Amgen Inc Chimeric receptors to flt3 and methods of use thereof
US11570992B2 (en) 2016-04-01 2023-02-07 Basf Se Bicyclic compounds
PL3436079T3 (pl) 2016-04-01 2021-12-20 Kite Pharma, Inc. Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania
PT3436030T (pt) 2016-04-01 2022-11-18 Amgen Inc Recetores quiméricos e métodos para a sua utilização
US10730884B2 (en) 2016-04-01 2020-08-04 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG10202009589UA (en) 2016-04-01 2020-10-29 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
WO2018167952A1 (ja) 2017-03-17 2018-09-20 三菱電機株式会社 アダプティブアレーアンテナ装置
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
UA125970C2 (uk) 2017-05-22 2022-07-20 Янссен Фармасьютікалз, Інк. Заміщені похідні індоліну як інгібітори реплікації вірусів денге
US11407715B2 (en) 2017-05-22 2022-08-09 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
AU2016259677A1 (en) 2017-10-26
DK3294738T3 (da) 2021-06-28
IL255430B (en) 2020-03-31
UA121332C2 (uk) 2020-05-12
PE20180232A1 (es) 2018-01-31
EP3896072A1 (en) 2021-10-20
JP2018515495A (ja) 2018-06-14
KR20180002644A (ko) 2018-01-08
PH12017502000A1 (en) 2018-03-26
US10919854B2 (en) 2021-02-16
US20240182414A1 (en) 2024-06-06
WO2016180696A1 (en) 2016-11-17
CN107873022A (zh) 2018-04-03
HK1252496A1 (zh) 2019-05-31
EP3896072B1 (en) 2022-11-16
CN113045476A (zh) 2021-06-29
US10696632B2 (en) 2020-06-30
EA201792429A1 (ru) 2018-02-28
RS62029B1 (sr) 2021-07-30
TW201704208A (zh) 2017-02-01
SG10201900315SA (en) 2019-02-27
CR20170490A (es) 2018-03-08
PH12017502000B1 (en) 2018-03-26
MX2017014293A (es) 2018-08-09
ECSP22023220A (es) 2022-05-31
NZ765879A (en) 2024-09-27
JP2022166289A (ja) 2022-11-01
AU2020273314A1 (en) 2020-12-17
IL272814B (en) 2021-02-28
TW202041499A (zh) 2020-11-16
ZA202002435B (en) 2023-03-29
US12172959B2 (en) 2024-12-24
JOP20210109A1 (ar) 2023-01-30
CN113045476B (zh) 2024-07-16
MX2020011156A (es) 2022-04-21
MD3294738T2 (ro) 2021-08-31
US20210171462A1 (en) 2021-06-10
MY198339A (en) 2023-08-27
SMT202100367T1 (it) 2021-07-12
JOP20160086B1 (ar) 2021-08-17
ES2877404T3 (es) 2021-11-16
UY36674A (es) 2016-11-30
ZA201707524B (en) 2024-06-26
HK1252446A1 (zh) 2019-05-24
SI3294738T1 (sl) 2021-08-31
IL272814A (en) 2020-04-30
UA128183C2 (uk) 2024-05-01
PL3294738T3 (pl) 2021-12-13
EP3294738A1 (en) 2018-03-21
CN111303000A (zh) 2020-06-19
CR20200152A (es) 2020-09-08
ECSP17073878A (es) 2018-02-28
CO2017012381A2 (es) 2018-03-28
JP2021138752A (ja) 2021-09-16
JP7451626B2 (ja) 2024-03-18
JP2020125316A (ja) 2020-08-20
GT201700234A (es) 2018-11-26
IL255430A0 (en) 2017-12-31
CA2981845A1 (en) 2016-11-17
MX391754B (es) 2025-03-21
PE20221579A1 (es) 2022-10-06
EA034978B1 (ru) 2020-04-14
UY39706A (es) 2022-05-31
US20180346419A1 (en) 2018-12-06
LT3294738T (lt) 2021-08-25
NI201700137A (es) 2019-05-07
US20250230127A1 (en) 2025-07-17
EP3294738B1 (en) 2021-04-07
CA2981845C (en) 2022-03-08
MX383932B (es) 2025-03-14
CN111303000B (zh) 2023-11-28
AU2016259677B2 (en) 2020-10-01
KR102610493B1 (ko) 2023-12-05
JP6752821B2 (ja) 2020-09-09
KR20210048578A (ko) 2021-05-03
TWI744963B (zh) 2021-11-01
CN107873022B (zh) 2021-03-12
US20200270209A1 (en) 2020-08-27
US11827602B2 (en) 2023-11-28
NZ736934A (en) 2023-11-24
TWI725969B (zh) 2021-05-01
ES2941674T3 (es) 2023-05-24
AU2020273314B2 (en) 2021-10-21
CY1124548T1 (el) 2022-07-22
HUE054724T2 (hu) 2021-09-28
JP7132399B2 (ja) 2022-09-06
KR102610491B1 (ko) 2023-12-06
HRP20210675T1 (hr) 2021-06-25
SV2017005557A (es) 2018-06-26
BR112017023904A2 (pt) 2018-07-17
JP6898493B2 (ja) 2021-07-07

Similar Documents

Publication Publication Date Title
CL2017002817A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue
CL2018002784A1 (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicación vírica del dengue.
CO2018003471A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
CO2018003369A2 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue
CL2018002729A1 (es) Derivados de indol sustituidos como inhibidores de la replicación vírica del dengue.
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
CL2017000782A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación del virus del dengue
JOP20180025A1 (ar) مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CL2018002718A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue.
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
UY36518A (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue